Alexander White

Observation of Wave-Packet Branching through an Engineered Conical Intersection

Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation

T cell–intrinsic prostaglandin E2-EP2/EP4 signaling is critical in pathogenic TH17 cell–driven inflammation

Elements of cancer immunity and the cancer–immune set point

Myasthenia Gravis

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Antibodies to watch in 2016

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Psoriasis

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Psoriasis pathogenesis and the development of novel targeted immune therapies

Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions

The JAK/STAT signaling pathway: from bench to clinic

Drug development in the era of precision medicine

Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies

Ulcerative colitis

PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment

Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis

Light-Driven and Phonon-Assisted Dynamics in Organic and Semiconductor Nanostructures

Psoriasis Pathogenesis and Treatment

Expanded Theory of H- and J-Molecular Aggregates: The Effects of Vibronic Coupling and Intermolecular Charge Transfer

Molecular beam kinetics: Long-lived collision complexes in reactions of K, Rb, and Cs with SnCl4 and SF6

Formation of Positive and Negative Ions on Rhenium, Oxygenated Tungsten, Hafnium, Lanthanum Hexaboride, and Thoriated Tungsten Surfaces

Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease

Stark hyperfine structure of hydrogen bromide

Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes

Proenkephalin⁺regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function

Reactive Oxygen Species (ROS)-Based Nanomedicine

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

Non-adiabatic Excited-State Molecular Dynamics: Theory and Applications for Modeling Photophysics in Extended Molecular Materials

The Production of Halogen Negative Ions at the Surface of a Thoriated Tungsten Filament

Semiclassical Monte Carlo: A first principles approach to non-adiabatic molecular dynamics